Some studies have recently demonstrated that tumor infiltrating immune cell IHC PD-L1 expression predict responses to Atezolizumab stronger than tumor PD-L1 expression [44], and that combining both tumor-infiltrating lymphocytes and IHC PD-L1 expression status, allow to identify four different subgroup of tumor microenvironment, which could benefit from different treatment strategies, including combination therapies [45]. Here, CD274 is linked to neoplasm.